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Abstract
Summary Fibroblast growth factor 23 (FGF23) is grossly
elevated in Gambian children with rickets and, at a lower
prevalence, in those without bone deformities. We used
western blotting to mimic the detection capabilities of the
C-terminal FGF23 enzyme-linked immunosorbent assay
(ELISA). Only intact FGF23 hormone was present in Gam-
bian plasma samples from children with and without rickets.
Introduction Elevated circulating FGF23 concentrations
have been detected in plasma samples from Gambian chil-
dren using the C-terminal Immutopics ELISA. The Immu-
topics ELISA detects both the intact FGF23 hormone and
the C-terminal fragment. The aim of this study was to
determine whether the elevated FGF23 concentrations as
detected by the ELISA were predominantly due to a high
proportion of intact FGF23 hormone and/or C-terminal
FGF23 fragments.
Methods Stored, frozen plasma samples from previous stud-
ies of Gambian children with known concentrations of
FGF23 as determined by C-terminal Immutopics ELISA
assay, were selected for western blotting analysis: from
children with rickets-like bone deformities (n04) and local
controls (n04), with elevated >900 RU/ml (n02) and normal
<30 RU/ml (n02; from each group). The anti-FGF23 poly-
clonal antibody that recognizes the C-terminal of FGF23 (as
used in the Immutopics kit) was used as the primary antibody
and the anti-IgG polyclonal antibody conjugated to horserad-
ish peroxidase (HRP) was used as the secondary antibody.
Results Firstly, C-terminal FGF23 fragments, although de-
tectable in standards from the Immutopics ELISA kit, were
not in the Gambian plasma samples. Secondly, there was no
difference in the size of FGF23 molecules present in plasma
from children with rickets-like bone deformities and chil-
dren from the local community.
Conclusions Western blotting has provided evidence that
elevated FGF23 concentrations, as determined by the C-
terminal Immutopics ELISA, measured in Gambian children
with and without rickets-like bone deformities was not
caused by an increased proportion of circulating inactive
C-terminal fragments.
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Introduction
Fibroblast growth factor 23 (FGF23) is a phosphate-
regulating hormone produced primarily by osteocytes [1].
FGF23 expression is predominantly regulated by plasma
phosphate (P) [2] and 1,25-dihydroxyvitamin D (1,25-
(OH)2D) [3]. The principal target organ of FGF23 is the
kidney where it causes the internalization of sodium–phos-
phate cotransporters in renal tubular cells and the suppres-
sion of 1α-hydroxylase activity [4], thus decreasing plasma
P by increasing urinary phosphate excretion and down-
regulating 1,25-(OH)2D concentrations, respectively.
The FGF23 gene encodes the 251 amino acid FGF23
peptide, which includes a signal peptide (SP) of 24 amino
acids. Prior to secretion the SP is cleaved to form the intact
FGF23 protein. The intact FGF23 protein contains the argi-
nine–X–X–arginine (RXXR) motif which is a protease
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recognition site [5]. When proteolytically cleaved between
Arg179 and Ser180 the intact FGF23 (~32 kDa) forms an N-
and C-terminal (~12 kDa) fragment (Fig. 1). It is thought
that only the intact FGF23 protein is biologically functional
and that the cleavage step forming the N- and C-terminal
fragments renders the protein inactive [6].
There are currently two commercially available enzyme-
linked immunosorbent assays (ELISA) for measurement of
FGF23 concentration, namely the Kainos Intact FGF23
ELISA (Kainos Laboratories, Inc., Tokyo, Japan) and the
Immutopics C-terminal FGF23 ELISA (Immutopics, Inc.,
CA, USA). The Intact ELISA uses two antibodies that
recognize the N-terminal and C-terminal regions and there-
fore only recognizes the full, intact FGF23 hormone prior to
proteolytic cleavage. However, the two antibodies used in
the C-terminal ELISA detect epitopes within the C-terminal
region and therefore recognizes both the intact hormone and
the C-terminal fragment.
Grossly elevated FGF23 concentrations have been
detected in a large percentage of Gambian children with
rickets-like bone deformities using the C-terminal ELISA
[7]. These were associated with elevated 1,25-(OH)2D and,
for patients with active rickets, hypophosphatemia [7, 8].
Chronic calcium deficiency has been proposed as a likely
etiological factor [7]. Additionally, albeit at a lower preva-
lence, elevated FGF23 concentrations have also been
detected in a small percentage of local reference children
with no signs of bone deformities [9]. The aim of the study
was to determine whether C-terminal FGF23 fragments
were present in Gambian plasma samples and therefore
detected using the Immutopics ELISA and if this was dif-
ferent in plasma from children with and without rickets-like
bone deformities. Western blot analysis was used with the
anti-FGF23 polyclonal antibody that recognizes the C-
terminal of FGF23 (as used in the Immutopics kit) as the
primary antibody and the anti-IgG polyclonal antibody con-
jugated to HRP as the secondary antibody. This method was
intended to replicate the detection capabilities of the
Immutopics ELISA and to thus identify what FGF23 pro-
tein/fragments were being detected.
Methods
Subject population
Fasted EDTA plasma samples (n08) from an etiological
study of rickets in Gambian children were selected from
stored frozen samples collected from children with a history
of rickets-like bone deformities and from the local commu-
nity [7–9] (Fig. 2b) in whom plasma FGF23 (C-terminal
ELISA; Immutopics, USA), phosphate (colorimetric; Koni
Analyser 20i, Finland) and 1,25-(OH)2D (radioimmunoas-
say; IDS, UK) concentrations had been previously deter-
mined. According to the manufacturer’s instruction, FGF23
concentration at 25–125 RU/ml is regarded as the normal
range. For the western blot analysis, we selected four chil-
dren (two with and two without a history of rickets-like
bone deformity) with a very high FGF23 (>900 RU/ml)
and four children (two with and two without a history of
rickets-like bone deformity) with FGF23 concentration
within the normal range. None of the subjects had active
disease or hypophosphatemia at the time the blood sample
was taken [8, 9]. Ethical approval was obtained from The
Gambian Government/MRC Laboratories Joint Ethics Com-
mittee to conduct further studies on FGF23 using these
stored samples.
SDS-PAGE and western blot analysis
Plasma samples and standards from the ELISA kit (50 μl)
were filtered using 50 kDa Amicon ultra centrifugal filters
(Milipore, UK) to remove proteins with a molecular weight
greater than 50 kDa. A 5 μl aliquot of plasma filtrate was
mixed with 1 μl NuPAGE® reducing agent, 2.5 μl
NuPAGE® sample buffer and 1.5 μl of water according to
manufacturer’s instructions (Invitrogen Ltd, Paisley, UK).
Any bubbles were removed and the samples were denatured
by heating for 15 min at 75 °C and then placing on ice for
10 min. The samples were then loaded onto NuPage® 4–
12 % Bis-Tris gels (Invitrogen Ltd, Paisley, UK) and were
separated at 200 V for 25 min. The proteins were then
transferred onto a nitrocellulose membrane (Invitrogen
Ltd, Paisley, UK) using the Xcell blot II Module (Invitrogen
Ltd, UK) for 1 h at 30 V using NuPAGE® transfer buffer
(Invitrogen Ltd, Paisley, UK) according to manufacturer’s
instructions. Membranes were incubated in blocking solu-
tion (5 % dry fat-free milk powder in phosphate buffered
saline (PBS)–Tween solution (PBS with 0.1 % Tween-20;
Sigma-Aldrich Company Ltd, Dorset, UK) for 2 h at room
temperature. Membranes were then incubated in the primary





N- and C-terminal FGF23 fragments
FGF23 protein with signal peptide
Fig. 1 Schematic of the FGF23 protein starting with the full FGF23
product (251 amino acids), the signal peptide (24 amino acids) is then
cleaved off to produce the intact FGF23 hormone which is considered
biologically active. Proteolytic cleavage then occurs at the end of the
RXXR motif between R179 and S180 to produce the biologically inac-
tive N- and C-terminal fragments. Both the intact hormone and the C-
terminal fragments are recognized by the C-terminal Immutopics
ELISA assay [8]
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antibody, anti-FGF23 polyclonal antibody that recognizes
the C-terminal of FGF23, diluted 1:1,000 with the blocking
solution for 1 h at room temperature. Membranes were then
washed with PBS-Tween and then incubated with the sec-
ondary antibody, donkey polyclonal antibody to Goat IgG
conjugated to HRP (Abcam, Cambridge, UK), diluted
1:2,000 in the blocking solution for 30 min at room temper-
ature. Membranes were then washed with PBS-Tween and
incubated with the substrate (Amersham ECL Plus Western
Blotting Detection System; GE Healthcare Life Sciences,
UK) for a short time before being exposed to a CCD camera
(Alpha Innotech Imager) to capture the resulting chemilu-
minescent signal.
Protein staining
After SDS-PAGE, the gels were stained using the Colloidal
Blue Staining Kit (Novex®, Invitrogen Ltd, Paisley, UK)
and dried using DryEase® Mini-Gel Drying System (Invi-
trogen Ltd, Paisley, UK) according to manufacturer’s
instructions.
Results
Using the anti-FGF23 polyclonal antibody that recognizes
the C-terminal of FGF23, two bands were detected in the
standard material from the ELISA kit namely, at approxi-
mately ~32 kDa and at a lower molecular weight ~12 kDa
suggestive of the full-length intact FGF23 and C-terminal
fragment, respectively. This indicated the western blot meth-
od is capable of detecting both intact and C-terminal FGF23
fragments. The Gambian plasma samples were then used in
the same method and only one band was detected, at
~32 kDa, namely the full-length intact FGF23 hormone.
There was no evidence of the presence of non-intact
FGF23 hormone in the plasma samples and there was no
difference in proteins detected in the samples from children
with rickets-like bone deformities (R1–R4) and from local
community children (C1–C4; Fig. 2a). Furthermore, protein
staining indicated a ~32 kDa band in both the plasma
samples and the standard material and a lower molecular
weight band (~12 kDa) in the standard material but there
were no low molecular weight proteins in the plasma
samples.
Discussion
We have previously reported the presence of elevated
FGF23 concentrations in Gambian children with a his-
tory of rickets-like bone deformities [7, 8] as deter-
mined by the C-terminal Immutopics ELISA assay.
Albeit at a lesser prevalence, we have also reported
elevated FGF23 concentrations in children from the
local community [8]. It has been suggested that these
measurements could be a reflection of the inactive C-
terminal fragments detected by the Immutopics ELISA
and therefore not a true reflection of the concentrations
of biologically functional intact FGF23 hormone. In
order to explore this eventuality we used the same
antibody as the C-terminal Immutopics ELISA kit in a
western blot to determine which protein fragments were
being detected by the ELISA. This confirmed detectable
fragments in the standard material but not in the Gam-
bian samples. This suggests that the high FGF23 con-
centrations, as measured by the C-terminal Immutopics
ELISA in Gambian children with and without bone
deformities, are a reflection of circulating intact FGF23
protein rather than high levels of cleaved product. Fur-
thermore, protein staining indicated that there were no
proteins of low molecular weight in the plasma samples
suggesting the absence of any type FGF23 fragments,
not only C-terminal fragments. Limitations of this study
include the small number of plasma samples available
for the analysis. In conclusion, a difference in propor-
tion of cleaved FGF23 hormone does not explain the
presence of high FGF23 in Gambian children with
rickets-like bone deformities and in children from the
local community [8].
Sample R1-H R2-H R3-N R4-N C1-H C2-H C3-N C4-N
FGF23 
(RU/ml)
3091 928 25 28 1473 1427 27 26
P 
(mmol/l)
1.55 1.50 1.49 1.63 1.35 1.38 1.61 1.46
1,25-(OH)2D
(pmol/l)
259 392 170 261 243 254 209 129
a
b
Fig. 2 Western blot a of plasma samples from four rickets children
(R1-R4) and four local community children with b previously mea-
sured elevated (H) and normal (N) FGF23 concentrations, plasma
phosphate (P) and 1,25-dihydroxyvitamin D (1,25-(OH)2D) and a
standard from the Immutopics ELISA kit. The arrows indicate the
intact FGF23 protein and the C-terminal fragment. There is no evi-
dence of C-terminal protein in the plasma samples but there is in the
standard a
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